Published :
Tables : 43
Figures : 41
Category : Healthcare
No. of Pages : 247
Report Code : HC-1126
Immune Repertoire Sequencing Market Introduction Immune repertoire sequencing market is forecasted to value over US$ 175 Million by 2027 end and register a CAGR of over 7.5% from 2020 to 2027. Human adaptive immune system protection is brought to the surface of B-cell receptor (BCR) and T-cell receptor(TCR) by receptors. Advancements in next-generation sequencing (NGS) have allowed the birth of new technology in the form of immune repertoire sequencing. It delves in determining the region of the receptors. It helps in delivering information regarding the antigen-specific present within lymphocytes. Increasing support from government regarding pharmacogenomics-based drug recovery has boosted the growth of the market. The rapid increase in multiple therapeutic areas like pain management, infectious diseases, cardiology, and oncology is stimulating the size of the market as well. In addition, various organizations aiming to look for solutions regarding biomarkers in the immune system has also been driving the growth of the market. Manufacturers merging is also fueling the growth of the market. For example, Ambry Genetics and ArcherDX Inc. merged together to deliver immune repertoire sequencing services to customers of the biopharmaceutical. The immune repertoire sequencing market is segmented by product, by application, and by the end user. By product, the market is bifurcated into assay kits and software & services. The assay kits are further divided into TCR Kits and BCR Kits. Assay kit is expected to hold a major share of the market in the forecast period. TCR plays an essential role in the human adaptive immune system. It recalls, destructs and recognizes the pathogenic agents. Multiple companies are looking for merging in order to develop repertoire sequencing kits for immunotherapy response of a specific kind. For example, MIODx and DiaCarta collaborated together to develop MIODX's ClonoMapto predict the response of the patient to immunotherapy. On the basis of software & services, the market is bifurcated into analytical software, sequencing services, and data analysis services. The end users of the market are infectious diseases, vaccine development, cancer immunotherapy, autoimmune disease, and transplant rejection & tolerance. Rising infectious diseases, advancement in vaccine development and research regarding cancer immunotherapy is expected to drive the growth of the market. In terms of region, North America is expected to hold a vast share of the market. Presence of a vast number of prominent players alongside growing attention towards novel technology for immune repertoire sequencing remains the key factor behind the growth of the market in the region. 10x Genomics Inc, a US-based company included 5'Unbiased Enrichment Kit to immune repertoire sequencing. Europe is expected to achieve the highest growth in the forecast period. The increased funding by the government alongside rising healthcare expenditure is expected to expand the size of the market in the region. Asia-Pacific region is also predicted to show immense growth of the market in the coming years. Rising health infrastructure in developing countries like China and Japan is also boosting the growth of the market in the region. Prominent players of the market are: ABVITRO (NOW JUNO THERAPEUTICS), ADAPTIVE BIOTECHNOLOGIES, AGILENT TECHNOLOGIES, ARCHERDX, INC., BGI, ILLUMINA, INC., IREPERTOIRE, INC., OXFORD NANOPORE TECHNOLOGIES, LTD, PACIFIC BIOSCIENCES, Qiagen N.V., Takara Bio Inc., CD Genomics, Roche Holding AG and Thermo Fisher Scientific Immune Repertoire Sequencing Market Segmentation: By Product Instrument NGS PCR Assay, Kits and Reagent TCR Kits Human TCR Kits Mouse TCR Kits BCR Kits Human BCR Kits Mouse BCR Kits Analytical Software TCR Analysis Solutions BCR Analysis Solutions TCR & BCR Analysis Solutions Services Pre-Sequencing Services Sequencing Services Data Analysis Services By Application Biomarker Discovery Autoimmune Diseases Cancer Immunotherapy Infectious Disease Research Asthma and Allergy Research Vaccine Development Immunodeficiency Identification Others (If Any) By End User Diagnostic Labs Pharmaceutical and Biotech Companies Research Institutes Others (If Any) By Region North America Europe Asia-Pacific Rest of the world Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the immune repertoire sequencing market based on the products, application, end users and region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Immune repertoire sequencing market is forecasted to value over US$ 175 Million by 2027 end and register a CAGR of over 7.5% from 2020 to 2027. Human adaptive immune system protection is brought to the surface of B-cell receptor (BCR) and T-cell receptor(TCR) by receptors. Advancements in next-generation sequencing (NGS) have allowed the birth of new technology in the form of immune repertoire sequencing. It delves in determining the region of the receptors. It helps in delivering information regarding the antigen-specific present within lymphocytes.
Increasing support from government regarding pharmacogenomics-based drug recovery has boosted the growth of the market. The rapid increase in multiple therapeutic areas like pain management, infectious diseases, cardiology, and oncology is stimulating the size of the market as well. In addition, various organizations aiming to look for solutions regarding biomarkers in the immune system has also been driving the growth of the market. Manufacturers merging is also fueling the growth of the market. For example, Ambry Genetics and ArcherDX Inc. merged together to deliver immune repertoire sequencing services to customers of the biopharmaceutical.
The immune repertoire sequencing market is segmented by product, by application, and by the end user. By product, the market is bifurcated into assay kits and software & services. The assay kits are further divided into TCR Kits and BCR Kits. Assay kit is expected to hold a major share of the market in the forecast period.
TCR plays an essential role in the human adaptive immune system. It recalls, destructs and recognizes the pathogenic agents. Multiple companies are looking for merging in order to develop repertoire sequencing kits for immunotherapy response of a specific kind. For example, MIODx and DiaCarta collaborated together to develop MIODX's ClonoMapto predict the response of the patient to immunotherapy.
On the basis of software & services, the market is bifurcated into analytical software, sequencing services, and data analysis services. The end users of the market are infectious diseases, vaccine development, cancer immunotherapy, autoimmune disease, and transplant rejection & tolerance. Rising infectious diseases, advancement in vaccine development and research regarding cancer immunotherapy is expected to drive the growth of the market.
In terms of region, North America is expected to hold a vast share of the market. Presence of a vast number of prominent players alongside growing attention towards novel technology for immune repertoire sequencing remains the key factor behind the growth of the market in the region. 10x Genomics Inc, a US-based company included 5'Unbiased Enrichment Kit to immune repertoire sequencing.
Europe is expected to achieve the highest growth in the forecast period. The increased funding by the government alongside rising healthcare expenditure is expected to expand the size of the market in the region. Asia-Pacific region is also predicted to show immense growth of the market in the coming years. Rising health infrastructure in developing countries like China and Japan is also boosting the growth of the market in the region.
Prominent players of the market are:
ABVITRO (NOW JUNO THERAPEUTICS), ADAPTIVE BIOTECHNOLOGIES, AGILENT TECHNOLOGIES, ARCHERDX, INC., BGI, ILLUMINA, INC., IREPERTOIRE, INC., OXFORD NANOPORE TECHNOLOGIES, LTD, PACIFIC BIOSCIENCES, Qiagen N.V., Takara Bio Inc., CD Genomics, Roche Holding AG and Thermo Fisher Scientific
Immune Repertoire Sequencing Market Segmentation:
By Product
By Application
By End User
By Region
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the immune repertoire sequencing market based on the products, application, end users and region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Application Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Disease Indication Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Immune Repertoire Sequencing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Application Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Market Analysis Tools 6.1. Application Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Disease Indication Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Disease Indication Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Immune Repertoire Sequencing Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Instrument 7.1.1. NGS 7.1.2. PCR 7.2. Assay, Kits and Reagent 7.2.1. TCR Kits 7.2.1.1. Human TCR Kits 7.2.1.2. Mouse TCR Kits 7.2.2. BCR Kits 7.2.2.1. Human BCR Kits 7.2.2.2. Mouse BCR Kits 7.3. Analytical Software 7.3.1. TCR Analysis Solutions 7.3.2. BCR Analysis Solutions 7.3.3. TCR & BCR Analysis Solutions 7.4. Services 7.4.1. Pre-Sequencing Services 7.4.2. Sequencing Services 7.4.3. Data Analysis Services 8. Global Immune Repertoire Sequencing Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Biomarker Discovery 8.2. Autoimmune Diseases 8.3. Cancer Immunotherapy 8.4. Infectious Disease Research 8.5. Asthma and Allergy Research 8.6. Vaccine Development 8.7. Immunodeficiency Identification 8.8. Others (If Any) 9. Global Immune Repertoire Sequencing Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Diagnostic Labs 9.2. Pharmaceutical and Biotech Companies 9.3. Research Institutes 9.4. Others (If Any) 10. North America Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2020-2027 11. Latin America Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2020-2027 12. Europe Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2020-2027 13. Asia Pacific Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Immune Repertoire Sequencing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Saudi Arabia 14.2.2. UAE 14.2.3. South Africa 14.2.4. Egypt 14.3. Market Size (USD Million) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. ABVITRO (NOW JUNO THERAPEUTICS) 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. ADAPTIVE BIOTECHNOLOGIES 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. AGILENT TECHNOLOGIES 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. ARCHERDX, INC. 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 BGI 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 ILLUMINA, INC. 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. IREPERTOIRE, INC. 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. OXFORD NANOPORE TECHNOLOGIES, LTD 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. PACIFIC BIOSCIENCES 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Qiagen N.V. 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11 Takara Bio Inc. 15.11.1. Company Overview 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12 Thermo Fisher Scientific 15.12.1. Company Overview 15.12.2. Product Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13. CD Genomics 15.13.1. Company Overview 15.13.2. Product Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 15.14. Roche Holding AG 15.14.1. Company Overview 15.14.2. Product Portfolio 15.14.3. SWOT Analysis 15.14.4. Financial Overview 15.14.5. Strategic Overview 16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics